Shire Update Call for Investors

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Shire Update Call for Investors Dublin, Ireland - June 20, 2014 - Shire plc ("Shire" or the "Company") (LSE:SHP, NASDAQ: SHPG) announces that, following today's earlier announcementconcerning the Board of Shire's rejection of AbbVie Inc's unsolicited andhighly conditional proposal regarding the possible cash and share offer for theCompany, Shire intends to host an investor call with management on Monday June23, 2014 at 1pm BST / 8am EDT. The details of the conference call are as follows: UK dial in: 08082370030 or 02031394830 US dial in: 1866 928 7517 or 1 718 873 9077 International Access http://wpc.1726.planetstream.net/001726/Numbers: FEL_Events_International_Access_List.pdf Password/Conf ID: 40849384# Live Webcast: http://www.shire.com/shireplc/en/investors Replay: A replay of the presentation will be available for two weeks by phone and bywebcast for three months. Details can be found on our Investor Relationswebsite http://www.shire.com/shireplc/en/investors. For further information please contact: Investor Relations Jeff Poulton [email protected] +1 781 482 0945 Sarah Elton-Farr [email protected] +44 1256 894157 Media Jessica Mann [email protected] +44 1256 894 280 Stephanie Fagan [email protected] +1 781 482 0460 ACCESS TO CALL AND PRESENTATION The investor call and the presentation are not directed at, or to be accessedor attended by, persons located or resident in any jurisdiction where therelevant action would constitute a violation of the relevant laws andregulations of such jurisdiction or would result in a requirement to complywith any governmental or other consent or any registration, filing or otherformality which Shire regards as unduly onerous. All persons resident orlocated outside the United Kingdom or the United States who wish to attend oraccess the call or materials must first satisfy themselves that they are notsubject to any local requirements that prohibit or restrict them from doing soand should inform themselves of, and observe, any applicable legal orregulatory requirements applicable in their jurisdiction. Shire and itsadvisers do not assume any responsibility for any violation by any person ofany of these restrictions. The information provided during the call and in the presentation is being madeavailable in good faith and for information purposes only and does notconstitute an offer to sell or otherwise dispose of or an invitation orsolicitation of any offer to purchase or subscribe for any securities orotherwise in any jurisdiction in which such offer or solicitation is unlawful. NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We focus on providing treatments in Neuroscience, Rare Diseases,Gastrointestinal, and Internal Medicine and we are developing treatments forsymptomatic conditions treated by specialist physicians in other targetedtherapeutic areas, such as Ophthalmology. www.shire.com Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release www.shire.com